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ABSTRACT 
 Histone deacetylase enzymes modify epigenetic characteristics of a genome by 
removing acetyl groups from histone proteins in chromatin. Histone deacetylase 
inhibitors work by stopping this activity which can have various results in a cell including 
apoptosis, cell cycle arrest, differentiation, and migration. The purpose of these 
experiments was to see how largazole, a histone deacetylase inhibitor, affected cell 
viability for breast cancer and associated metastatic cell lines in both normoxic and 
hypoxic conditions. The experiment was completed by setting up two 96-well plates with 
varying concentrations of largazole and conducting a sulforhodamine viability assay. The 
specific cell lines used in the experiment were MCF-7, MDA-MB-231, MCF-7 BoM, and 
MDA-MB-231 BoM. Largazole showed promise in treating triple-negative breast cancer, 
triple-negative breast cancer metastasis, and estrogen receptor-positive breast cancers. 
 
 vi 
 
PREFACE 
After my freshman year at the University of Mississippi, I had no doubt what the topic of 
my Honors College thesis would be: cancer research. Throughout my life, cancer had 
shaped and touched the lives of those around me until it eventually touched my life as 
well. Cancer is a non-discriminatory disease which affects the lives of millions of people 
around the world. This research project gave me insight on the complexity of cancer and 
the time required for proper and efficient research. I am incredibly thankful for the 
opportunity to study such an important disease which has affected so many people in my 
life. 
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1 Introduction 
1.1 Cancer Introduction & Breast Cancer 
 Breast cancer is a disease which affects both women and men throughout the 
world. In 2020, the American Cancer Society estimates 276,480 women and 2,620 men 
will be diagnosed with invasive breast cancer while 42,690 people will die from breast 
cancer in the United States (American Cancer Society, 2020). Breast cancer is the second 
most common cancer in women in the United States and is the second most common 
cancer in both genders worldwide (“Breast Cancer Statistics and Resources”). Given 
these statistics, the development of treatments and potential cures for breast cancer 
should be a primary focus for cancer research. 
 Although the meaning of the word “cancer” might seem simple, it refers to over 
one hundred disease types which can affect nearly any tissue in the body. Cancer, in 
short, is a disease caused by an increase in cell proliferation and a decrease in cell death. 
The actions of a cell are guided by a specific sequence of DNA known as the cellular 
genome. When a cell divides and replicates, the genome template must be precisely 
copied and passed on to ensure proper cellular functioning. However, because the human 
body has an estimated 30 trillion cells, errors in DNA replication are bound to occur 
resulting in cancerous cells. Normally, the body is able to eliminate such dangerous cells 
by apoptosis (programmed cell death), immune destruction, and many other mechanisms. 
Cancer cells are now known to have certain hallmark abilities which allow them to evade 
normal destruction: resisting cell death, sustaining proliferative signals, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, and 
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inducing angiogenesis (Hanahan and Weinberg, 2011). Although anyone has a chance to 
develop cancer, some people are more prone than others. 
  Breast cancer has both modifiable and non-modifiable factors which can affect 
the potential for developing the disease (Kluttig and Schmidt-Pokrzywniak, 2009). 
Examples of modifiable risk factors include diet, alcohol consumption, smoking, physical 
activity level, and weight (Kluttig and Schmidt-Pokrzywniak, 2009). Currently, no 
consistent or strong associations have been made between breast cancer occurrence and 
diet, smoking, or physical activity level (Kluttig and Schmidt-Pokrzywniak, 2009). 
Despite some inconclusive results, smoking has been shown to increase the risk of breast 
cancer in subsets of women with specific genetic mutations (Kluttig and Schmidt-
Pokrzywniak, 2009). Alcohol consumption has shown to be correlated with a greater risk 
of developing breast cancer; both pre- and post-menopausal women have shown a 7% 
increased risk for each additional 10 grams of alcohol consumed per day (Kluttig and 
Schmidt-Pokrzywniak, 2009). Weight had contrasting effects on women depending on if 
they were pre- or post-menopausal (Kluttig and Schmidt-Pokrzywniak, 2009). Pre-
menopausal women with a larger BMI had decreased risks of breast cancer while post-
menopausal women had increased risks of breast cancer (Kluttig and Schmidt-
Pokrzywniak, 2009). 
 Some of the non-modifiable risk factors of breast cancer include age, race, history 
of breast cancer, breast density, and genetic factors. Generally, as people age, they 
become more prone to developing all types of cancer. For breast cancer, both incidence 
and mortality increase with increasing age (Kluttig and Schmidt-Pokrzywniak, 2009). 
The incidence of breast cancer also varies greatly by country; the United States and 
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Northern Europe had the highest standardized rates with 50-100 per 100,000, and Asia 
had the lowest incident rates with 10-30 per 100,000 (Kluttig and Schmidt-Pokrzywniak, 
2009). For women under fifty, breast cancer incidence rates for Caucasians and African 
Americans were the same (Kluttig and Schmidt-Pokrzywniak, 2009). For women older 
than fifty, Caucasians had a higher incidence rate (351.9 per 100,000) compared to 
African Americans (292.2 per 100,000), but African Americans had greater breast cancer 
mortality rates (Kluttig and Schmidt-Pokrzywniak, 2009). Both high breast tissue density 
and a family history of breast cancer have been found to be associated with an increased 
risk for breast cancer (Kluttig and Schmidt-Pokrzywniak, 2009). Many genetic factors 
can also contribute to the likelihood of developing breast cancer. When mutated, BRCA1 
and BRCA2–two well-known susceptibility-associated genes–can result in a 65% and 
45% respective cumulative risk for a mutant carrier by age 70 (Kluttig and Schmidt-
Pokrzywniak, 2009). 
 Breast cancer is considered a highly heterogenous disease, meaning cases can 
differ greatly from one another; some cancers will have a good prognosis while others 
can be aggressive and malignant (Tao, et al., 2015). The classification of breast cancer 
tumors is influenced by many factors including morphological characteristics, 
histological grade, and specific receptor expression (Tao, et al., 2015). The 
morphological types of breast cancer range from infiltrating ductal or lobular carcinoma 
to tubular carcinomas and more (Tao, et al., 2015). The histological grade of breast 
cancers can vary especially based on time of breast cancer discovery. Smaller, tubular 
carcinomas are associated with earlier stages while infiltrating ductal carcinomas have a 
higher histological grade and are often associated with a larger size and metastasis (Tao, 
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et al., 2015). Breast tumors have been classified into five subgroups depending on the 
expression of the HER2 (Human Epidermal Growth Factor Receptor 2) oncogene and 
two types of receptors: estrogen receptors (ER) and progesterone receptors (PR) (Tao, et 
al., 2015). Estrogen receptor-positive tumors are more common than ER-negative tumors, 
and ER-positive tumors are generally smaller and lower in grade (Tao, et al., 2015). In 
triple negative breast cancer (TNBC), cancer cells do not express ER, PR, or HER2 
receptors. Triple-negative breast cancer makes up around 15% of breast cancer cases and 
is generally aggressive and associated with a poor prognosis (Tao, et al., 2015). An 
individual’s specific breast cancer type should be identified to effectively treat the disease 
and prevent tumor progression. 
 Tumors can become significantly more difficult to treat due to metastasis. More 
than 90% of cancer-related deaths are associated with metastasis which significantly 
decreases the effectiveness of conventional cancer treatments such as surgery, 
chemotherapy, and radiation (Rankin and Giaccia, 2016). Metastasis occurs when 
cancerous cells break free from a primary tumor and travel through the circulatory and 
lymphatic systems to establish a secondary tumor at a different site. Metastatic tumors 
require different treatment as they behave more like the tumor of origin rather than a 
tumor of the tissue metastasized (Chiang and Massague, 2008). Many tumors 
preferentially metastasize to certain organs; for example, breast cancer often metastasizes 
to the bones, lungs, brain, and liver (Chiang and Massague, 2008). When studying breast 
cancer metastasis in vitro, various cell lines can be used to model different situations. For 
example, the MCF-7 cell line is ER-positive while the MDA-MB-231 cell line is 
representative of TNBC (Neve, et al., 2006). Metastatic lines can be derived by having 
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cells mimic transendothelial migration and grow in the presence of bone marrow stromal 
cells to produce BoM (bone metastatic) cell lines (Arrigoni, et al., 2016). 
 
Figure 1: Tumor initiation and metastasis. 
 The microenvironment of a tumor also plays a role in breast tumor development 
and treatment. Tumors often have inadequate blood vessel vascularization which can 
result in hypoxia (lack of oxygen) in both primary and metastatic tumors (Knowles and 
Harris, 2001). Under normoxic (normal oxygen) conditions, oxygen prevents the 
accumulation and activation of hypoxia-inducible transcription factors HIF-1 and HIF-2 
in the cell (Rankin and Giaccia, 2016). When a cell experiences hypoxia, however, HIF-1 
and HIF-2 allow a cell to adapt to the low-oxygen environment by expressing genes 
which alter metabolism, apoptosis, cell proliferation, and more (Rankin and Giaccia, 
2016). Hypoxia and HIF activation have been clinically associated with metastasis 
promotion, poor survival, and tumor resistance to chemotherapy and radiation (Rankin 
and Giaccia, 2016). 
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 Currently, different treatments are available for breast cancer, and an individual’s 
course of treatment depends on several factors. For nonmetastatic breast cancer, the goals 
of treatment are to prevent reoccurrence and eradicate the tumor (Waks and Winer, 
2019). For people presenting with highly metastatic cancers, the goal is to prologue life 
while controlling symptoms (Waks and Winer, 2019). Breast cancer can be treated in 
many ways, including chemotherapy, radiation, surgery, and hormone therapy. 
1.2 Histone Deacetylase Inhibitors (HDACIs) 
 Although a single cell holds an entire cell’s genome, not every gene within the 
genome is expressed. The regularity of transcription for a gene varies greatly; some genes 
are transcribed constantly while others remain silenced. These differences in gene 
expression can result from epigenetic changes, or modifications to expressional patterns 
that do not alter the DNA sequence of a gene. Inside the nucleus of a cell, DNA is 
organized into chromatin which is made of repeating units called nucleosomes. A 
nucleosome contains 145-147 DNA base pairs wrapped around globular histone proteins 
made of H2A, H2B, H3, and H4 subunits connected by H1 linker histones (Biel, et al., 
2005). The amino termini of histone proteins are flexible, conserved regions on the 
surface of the histone (Biel, et al., 2005). The availability of the amino termini of histones 
make post-translational modifications possible, such as acetylation by histone 
acetyltransferases (HATs) at particular lysine residues or deacetylation by histone 
deacetylases (HDACs) (Biel, et al., 2005). Histone acetylation is associated with 
transcriptional activation and is found to a higher degree in euchromatin, or actively 
transcribed chromatin, compared to heterochromatin, or condensed and transcription-
inaccessible chromatin (Biel, et al., 2005). 
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 Almost forty years ago, the addition of butyric acid to cells in culture resulted in 
increased histone acetylation via HDAC inhibition (Halsall and Turner, 2016). The 
ability to change the amount and frequency of gene acetylation could result in an 
alternation of cell phenotype without changing genotype. This concept sparked the 
interest of cancer drug researchers and eventually led to the use of histone deacetylase 
inhibitors (HDACIs) in cancer treatment. The HDACIs block the activity of HDACs in 
the cell which generally results in increased acetylation of histones and other protein 
targets (Ververis, et al., 2013). With HDACs inhibited, HATs are able to acetylate DNA 
segments allowing for transcriptional activation of many genes. The effects of HDACIs 
on a cell can vary widely due to targeting both histones and other intracellular proteins, 
and genes can actually be either up or down regulated in response (Ververis, et al., 2013). 
HDACIs can result in varied cell responses such as apoptosis, cell cycle arrest, 
differentiation, and migration (Ververis, et al., 2013). 
 
Figure 2: HDAC inhibitors promote the acetylation of histones and nonhistone proteins by inhibiting the activity of 
HDAC enzymes. 
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 When HDACIs are introduced to a noncancerous cell, the cell needs to be able to 
adjust to the hyperacetylation without dying. Eukaryotic cells tolerate the 
hyperacetylation caused by HDACIs, but the exact tolerance mechanism is unknown 
(Halsall, et. al., 2015). In a study, cells showed an adaptive response to HDACIs by 
minimizing protein hyperacetylation, increasing methylation of histones at transcription 
start sites, and down regulating genes encoding lysine acetyltransferase (KAT) 
complexes to promote cell survival (Halsall, et. al., 2015). These three responses all 
contribute to alleviating the hyperacetylation caused by HDACIs. HDACIs are natural 
products which are often produced by bacteria. Since both bacteria and eukaryotic cells 
can live in the same environment, eukaryotic cells need to be able to mitigate the effects 
of HDACIs (Halsall, et. al., 2015). 
 Histone deacetylases (HDACs) are important biological enzymes which can 
influence development and disease via transcription (Haberland, et al., 2009). The HDAC 
superfamily contains many enzymes categorized into four classes: Class I HDACs 
including HDAC 1, 2, 3, and 8; Class IIa HDACs including HDAC 4, 5, 7, and 9; Class 
IIb HDACs including HDAC 6 and 10; and Class IV HDACs including HDAC 11 
(Haberland, et al., 2009). The experiment focused on Class I HDACs which have 
relatively simple structures (Haberland, et al., 2009). Class I HDACs localize to the 
nucleus, show enzyme activity towards histone substrates, and are expressed ubiquitously 
(Haberland, et al., 2009). Highly involved with cell proliferation, cell cycle regulation, 
and apoptosis, the deregulation of Class I HDACs has been associated with many forms 
of cancer including renal, colorectal, lung, pancreatic, and breast cancers (Barneda-
Zahonero and Parra, 2012). 
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 Epigenetic changes are known to be associated with cancer, and HDACs play an 
important role in epigenetic modifications which can alter gene transcription of 
oncogenes and tumor suppressor genes (Li and Seto, 2016). Currently, there are at least 
twenty-two HDACIs under clinical investigation, and four HDACIs have been approved 
to treat cancer by the FDA (Li and Seto, 2016). In preclinical trials, HDACIs have been 
shown to re-sensitize tumor cells to treatments by other antitumor or chemotherapeutic 
agents to which cells had become resistant (Li and Seto, 2016). The HDACIs have shown 
synergistic relationships with some DNA methyltransferases (DNMTs) and have great 
potential for future cancer treatments (Li and Seto, 2016). 
1.3 Largazole and Experiment Introduction 
 Largazole is a marine natural product produced by cyanobacteria of the genus 
Symploca (Hong and Luesch, 2012). Dolastin 10, a cancer clinical trial agent, is produced 
by cyanobacteria with the same genus (Hong and Luesch, 2012). Luesch and Paul were 
able to find another agent from the same genus of bacteria with antiproliferative activity 
in coastal Florida, and the agent was later identified and named largazole (Hong and 
Luesch, 2012). In preliminary tests, largazole showed differential cytotoxicity towards 
cancer cells, inhibiting them at nanomolar concentrations, while inhibiting other non-
cancer cells to a considerably lesser extent (Hong and Luesch, 2012). 
 
Figure 3: The chemical structure of largazole 
 13 
 Largazole is a cyclic molecule containing peptide bonds capable of inhibiting 
Class I HDACs (Hong and Luesch, 2012). Largazole shows great promise as an 
anticancer agent, and currently eleven different syntheses of the product have been 
recorded (Hong and Luesch, 2012). Largazole may interact with HDAC1, an enzyme 
which is overly expressed in some cancers (Hong and Luesch, 2012).  
 Under the guidance of Dr. Yu-Dong Zhou and with assistance from Hannah 
Carson, I tested the effectiveness of largazole on different breast cancer cell lines and 
associated BoM (bone metastatic) cell lines. The purpose of the experiment was to 
determine the effectiveness of largazole on breast cancer metastasis via a cell assay. 
  
 14 
2 Methods 
2.1 Background 
 The research project began with training in laboratory techniques in Spring 2019. 
After a change in topic, the final research project was designed and completed in Fall 
2019. At the same time, Dr. Zhou taught a course on the basics of cancer and current 
treatment options. The final project design was to treat both breast cancer and derived 
metastatic breast cancer cell lines with largazole to determine cell viability.  
2.2 Preparation of HDACi on Dilution Plate 
 Largazole was obtained from Professor Hendrik Luesch at the University of 
Florida College of Pharmacy. Largazole (a 100 µM stock solution) was serially diluted 
using a serum-free medium containing antibiotic. The compound was added at 2x the 
final concentration in volume to produce the correct concentration when added with the 
cells and their media. The mother plate was prepared at 2.5x volume to produce two SRB 
viability 96-well plates. The final concentrations of largazole used were 100, 30, 10, 3, 1, 
and 0.1 nM. Cycloheximide is a protein synthesis inhibitor which served as a positive 
control for the experiment as cycloheximide is known to reduce cell viability (PubChem 
Compound Database) 
2.3 Cell Lines and Cell Culture 
 Human breast tumor MCF-7 and MDA-MB-231 cells were obtained from the 
American Type Culture Collection (ATCC). The MCF-7-derived subclones MCF-7 BoM 
(BoM, bone metastatic) and MDA-MB-231-derived BoM were generated by J. Massagué 
at Memorial Sloan Kettering Cancer Center and were obtained from K. Watabe at Wake 
Forest. MDA-MB-231 is an aggressive, invasive, triple-negative breast cancer, and MCF-
 15 
7 is an ER-positive breast cancer cell line (“MDA-MB-231 Cell Line Profile”). The cells 
were maintained in RPMI 1640 media (Hyclone). Antibiotic was added to the cell media 
at a concentration of 1%, and the cells were grown at a temperature of 37ºC in an 
environment consisting of 95% air and 5% CO2. 
2.4 SRB Viability Assay under Normoxic and Hypoxic Conditions 
 The Sulforhodamine B (SRB) assay is a cost-effective way to test the cytotoxicity 
of a compound on various cell lines (Orellana and Kasinski, 2016). For the SRB viability 
assay, the different cell lines were seeded onto a 96-well plate in a volume of 100 µL 
10% FCS complete culture media at the desired density. First, cells were trypsinized 
using 1 mL trypsin and 9 mL cell culture media. The cells were then washed with more 
culture media and diluted to the following densities using a hemocytometer: MCF7 at 
30,000 cells/well, MDA-MB-231 at 20,000 cells/well, BoM lines to 15,000 cells/well. 
Next, 100 µL of the cell solution and 100 µL of the cell media were added to the 
respective positions on the 96-well plates to achieve the proper cell dilution and drug 
concentration. The cells were exposed to hypoxic (1% O2/5% CO2/94% N2) or normoxia 
(5% CO2/95% air) conditions for 48 hours. After incubation, 100 µL of media was 
removed from each well, and 20% trichloroacetic acid (TCA) and 1X PBS were added to 
each well. The plates were then put in the fridge at 4ºC for 1 hour, washed with water, 
and set in the hood to dry. Next, the wells were stained with 100 µL of 0.4% SRB for 10 
minutes at room temperature. The plates were then washed with 3X acetic acid and were 
laid out to dry. Finally, 100 µL/well of 10 mM Tris base was added to the wells, and the 
plates were allowed to shake for 10 minutes. Absorbance was measured using Tecan 
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SpectraFluor Plus plate reader at a range of 496-620 nm, and the difference in absorbance 
was used to calculate cell viability. 
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3 Results and Discussion 
 The purpose of the SRB viability assay was to determine the percent inhibition of 
Largazole on MDA-MB-231, MDA-MB-231 BoM, MCF-7, and MCF-7 BoM cell lines. 
The goal was to find IC50 values, or the concentration of drug at which cell viability was 
inhibited by half. However, the percent inhibition never reached this value. Instead, the 
highest inhibitory concentration for largazole was found for each cell line in both 
normoxia and hypoxic conditions. Figures were made using Prism 8 and Microsoft Word. 
 
Figure 4: Percent inhibition of cell viability by largazole 
 Both MCF-7 and MDA-MB-231 show greater inhibition in normoxic conditions. 
The triple-negative breast cancer cell line MDA-MB-231 required a much greater 
concentration of largazole in the hypoxic condition to achieve only 1% inhibition. The 
BoM cell lines show a greater percent inhibition in both normoxia and hypoxic 
conditions compared to their corresponding non-metastatic lines. The MCF-7 BoM cell 
line showed relatively the same percent inhibition in both normoxia and hypoxic 
conditions when treated with largazole (100 nM). The MDA-MB-231 BoM line showed 
greater inhibition in the normoxia condition, but was still inhibited in the hypoxia 
condition, with a treatment of only 1 nM of largazole. 
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Figure 5: Largazole SRB results 
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Figure 6: Effect of cycloheximide on cell viability under normoxic and hypoxic conditions 
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 Finally, Figure 6 shows the effects of cycloheximide compared to the media 
control on the cell lines in normoxia and hypoxic conditions. Overall cycloheximide 
reduced cell viability compared to the media control. However, in the MCF-7 and BoM 
lines, the hypoxia condition also significantly reduced cell viability in the media control. 
These results would suggest those two cell lines are very sensitive to oxygen 
concentrations. 
 In the figures above, both overlapping and large error bars can be seen. Since this 
was the experimenters’ first-time practicing cell culture, laboratory technique error was 
introduced into the experiment. Errors were also introducing via pipetting techniques 
which were constantly being improved throughout the entire process. 
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4 Conclusion 
 The purpose of the experiment was to test how largazole affected both breast 
cancer cell viability and metastasis in both normoxic and hypoxic conditions. The two 
metastatic breast cancer lines, MDA-MB-231 BoM and MCF-7 BoM, were generally 
found to have the overall highest inhibition in normoxic and hypoxic conditions. 
However, the MCF-7 BoM line required a much higher concentration of largazole in both 
conditions. Largazole was also found to be efficient in treating the non-metastatic lines, 
MDA-MB-231 and MCF-7, under normoxic conditions. Largazole, and potentially other 
histone deacetylase inhibitors, shows promise in treating triple-negative breast cancer, 
triple negative breast cancer metastasis, and ER-positive breast cancers. For future 
research, this experiment could be repeated with better laboratory technique to gain better 
insight. Additionally, this experiment could be repeated with different cell lines to see if 
largazole affects all ER-positive and TNBC cell lines in the same fashion. 
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